Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of TQA3810 in Healthy Subjects
NCT06431438Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQA3810 in Chronic Hepatitis B (CHB) (10 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Incidence of Adverse Events. Started Oct 2021; status: completed.
02
Drugs
TQA3810
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06431438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431438.